D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.93% |
| 2 | Consumer Discretionary | 10.48% |
| 3 | Healthcare | 8.56% |
| 4 | Communication Services | 8.41% |
| 5 | Financials | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
First Hawaiian
FHB
$3.42B
| $1.63M | ﹤0.01% |
59,502
-279
| -0.5% | -$7.49K |
|
|
GDEN
2627
DELISTED
Golden Entertainment
GDEN
| $1.63M | ﹤0.01% |
64,439
-40,726
| -39% | -$915K |
|
2628
CALL
Sinclair Inc
SBGI
$1.02B
| $1.63M | ﹤0.01% |
55,600
-9,100
| -14% | -$303K |
|
2629
Tandem Diabetes Care
TNDM
$1.22B
| $1.62M | ﹤0.01% |
18,381
-12,697
| -41% | -$1.18M |
|
|
CYBE
2630
DELISTED
Cyberoptics Corp
CYBE
| $1.62M | ﹤0.01% |
62,302
+23,147
| +59% | +$601K |
|
2631
PUT
GoDaddy
GDDY
$13.6B
| $1.61M | ﹤0.01% |
+20,800
| New | +$1.67M |
|
2632
Scansource
SCSC
$1.16B
| $1.61M | ﹤0.01% |
53,872
+966
| +2% | +$28K |
|
2633
CALL
Cerence
CRNC
$368M
| $1.61M | ﹤0.01% |
18,000
+10,000
| +125% | +$1.1M |
|
2634
Keros Therapeutics
KROS
$199M
| $1.61M | ﹤0.01% |
26,142
-29,060
| -53% | -$1.84M |
|
|
CUB
2635
DELISTED
Cubic Corporation
CUB
| $1.6M | ﹤0.01% |
21,518
-63,757
| -75% | -$4.35M |
|
|
BKCC
2636
DELISTED
BlackRock Capital Investment Corporation
BKCC
| $1.6M | ﹤0.01% |
478,514
-90,020
| -16% | -$286K |
|
2637
PUT
Beam Therapeutics
BEAM
$2.7B
| $1.6M | ﹤0.01% |
+20,000
| New | +$1.9M |
|
2638
CALL
Kraft Heinz
KHC
$32.4B
| $1.6M | ﹤0.01% |
40,000
-102,500
| -72% | -$3.69M |
|
|
KBAL
2639
DELISTED
Kimball International
KBAL
| $1.59M | ﹤0.01% |
113,710
-258,326
| -69% | -$3.35M |
|
2640
Vanguard FTSE Emerging Markets ETF
VWO
$119B
| $1.59M | ﹤0.01% |
30,520
-36,544
| -54% | -$1.95M |
|
2641
BridgeBio Pharma
BBIO
$16.8B
| $1.59M | ﹤0.01% |
+25,759
| New | +$1.69M |
|
2642
FNB Corp
FNB
$6.81B
| $1.59M | ﹤0.01% |
124,903
-473,725
| -79% | -$5.48M |
|
2643
PUT
Hershey
HSY
$37.2B
| $1.58M | ﹤0.01% |
10,000
-80,500
| -89% | -$12.1M |
|
2644
PUT
Goodyear
GT
$2.12B
| $1.58M | ﹤0.01% |
90,000
-158,000
| -64% | -$2.29M |
|
2645
City Holding Co
CHCO
$2.04B
| $1.58M | ﹤0.01% |
19,282
+11,431
| +146% | +$870K |
|
2646
CALL
Molson Coors Class B
TAP
$7.97B
| $1.57M | ﹤0.01% |
30,800
| – | – |
|
2647
PUT
Zoetis
ZTS
$32.5B
| $1.57M | ﹤0.01% |
10,000
-20,000
| -67% | -$3.17M |
|
2648
PUT
AB InBev
BUD
$161B
| $1.57M | ﹤0.01% |
25,000
-70,000
| -74% | -$4.52M |
|
2649
CALL
Papa John's
PZZA
$1.02B
| $1.57M | ﹤0.01% |
17,700
| – | – |
|
2650
AMN Healthcare
AMN
$1.35B
| $1.57M | ﹤0.01% |
+21,271
| New | +$1.58M |
|
Similar funds
D.E. Shaw & Co's Q1 2021 Portfolio in Review
As of Q1 2021, D.E. Shaw & Co held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
D.E. Shaw & Co withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Baidu worth $627M.
- D.E. Shaw & Co's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- D.E. Shaw & Co added most to Tesla in Q1 2021, an estimated $862M increase.
- D.E. Shaw & Co's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- D.E. Shaw & Co fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- D.E. Shaw & Co's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- D.E. Shaw & Co opened 825 new positions and closed 730 in Q1 2021.
- D.E. Shaw & Co's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.